Corbion NV (CSNVF) Q2 2024 Earnings Call Highlights: Strong Organic Growth and Strategic ...

GuruFocus News
4 min read

In This Article:

  • Volume Mix Growth: Q2 organic growth of 5.5%, leading to H1 growth of 3.6%.

  • Adjusted EBITDA: EUR 51.6 million in Q2, with an EBITDA margin of 15.3%.

  • Net Debt-to-EBITDA Ratio: 2.2 times.

  • Sales (Continued Operations): H1 2023 sales of EUR 642 million after excluding emulsifiers.

  • EBITDA Increase: EUR 17 million increase in H1 driven by health and nutrition.

  • Q2 Sales Increase: 2.3% increase in sales.

  • Q2 EBITDA Increase: 54% increase to EUR 41.6 million.

  • Tax Rate: 24%.

  • Functional Ingredients and Solutions Volume Mix Growth: Q2 growth of 3.2%.

  • Health and Nutrition Organic Sales Growth: H1 growth of 14.5%.

  • PLA Joint Venture Sales Growth: H1 organic growth of 14.1%, Q2 growth of 6.2%.

  • Free Cash Flow Guidance: Expected to deliver over EUR 50 million.

Release Date: August 08, 2024

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

  • Corbion NV (CSNVF) reported strong performance in H1 2024 with a 3.6% volume mix growth and a 5.5% organic growth in Q2.

  • The company achieved an adjusted EBITDA of EUR 51.6 million in Q2, marking a significant improvement in EBITDA margin to 15.3%.

  • The health and nutrition segment continues to grow at a double-digit rate with a high EBITDA margin, driven by strong demand for omega-3 in aquaculture and pet nutrition.

  • Corbion NV (CSNVF) successfully divested its emulsifier business, resulting in a positive free cash flow and a net debt-to-EBITDA ratio of 2.2 times.

  • The startup of the new lactic acid plant in Thailand is progressing well, expected to be a major value creation driver for the company in the coming years.

Negative Points

  • The biochemicals segment is experiencing market softness, particularly in semiconductors and agrochemicals.

  • Despite positive momentum, the company anticipates low single-digit negative pricing impact for the full year.

  • The PLA joint venture, while showing sales growth, is still affected by high sugar prices impacting margins.

  • The company faces challenges in fully compensating the stranded costs from the emulsifier divestment, with full compensation expected only by 2025.

  • Freight rates have been volatile and are creeping up, which could impact margins in the near term.

Q & A Highlights

Q: You realized organic EBITDA growth of close to 22% in H1, 46% in Q2. Why is the guidance for H2 growth only above 14%? A: Peter Kazius, CFO, explained that the strong outlook is based on prior year comparisons and strain optimization in health and nutrition, which already showed significant improvement from H1 2023 to H2 2023.

Recommended Stories